Kexing Biopharm (688136.SH): Ophthalmic Formulation GB10 Injection Receives Clinical Trial Approval

Former Construction Bureau Deputy Director Ventures into Pharma, Kexing Biopharm's Major Shareholder Cashes Out 1 Billion Before IPO

Kexing Biopharm Seeks China Approval for Hong Kong Listing

Kexing Biopharm Co.,Ltd. (688136.SH): Keying Medicine Plans to Transfer 5% Stake via Inquiry

BRIEF-Kexing Biopharm's Shareholder To Sell 5.0% Stake In Co

Kexing Biopharm Says Shareholder Plans to Sell 5.0% Stake in Co via Inquiry-Based Transfer

Kexing Biopharm Files for Hong Kong IPO

Kexing Biopharm (688136.SH) Submits H-Share Listing Application to HKEX and Publishes Application Materials

Kexing Biopharm Showcases Global Strategy and Partnership Opportunities at Cphi Frankfurt 2025

Kexing Biopharm's Sorafenib Generic Receives Approvals in Egypt and Peru

Kexing Biopharm Co.,Ltd. (688136.SH) Plans to Issue H Shares for Listing on Hong Kong Stock Exchange

Kexing Biopharm (688136.SH): Clinical Trial Registration Application for GB10 Injection Receives Regulatory Acceptance

Kexing Biopharm Unit's Respiratory Tract Infection Drug Lands on China's Breakthrough Therapy List

Kexing Biopharm (688136.SH): Human Interferon α-1b Inhalation Solution Included in Breakthrough Therapy Designation List

Kexing Biopharm's Controlling Shareholder Raises 750 Million Yuan Through 30% Discount Sale, Likely Paving Way for Hong Kong IPO

Uni-Bio Science Partners Kexing Biopharm to Commercialize Bogutai in Six Markets; Shares Rise 7%

Kexing Biopharm (688136.SH) Shareholder Keyi Pharmaceutical Plans Inquiry-Based Transfer of 5% Stake

Kexing Biopharm Says Major Shareholder Shenzhen Keyi Pharmaceutical Plans Sale of 5% Company Stake

BRIEF-Kexing Biopharm Says Major Shareholder Shenzhen Keyi Plans Sale Of 5% Stake

Uni-Bio Science Group and Kexing Biopharm Form Strategic Alliance to Globalize Osteoporosis Treatment Bogutai®